FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies

Barcelona, July 4, 2019.- Grifols, a leading global producer of plasma-derived medicines, announced today that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify is used to...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

Publication date: April 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 4Author(s): Saba Fekrvand, Reza Yazdani, Peter Olbrich, Andrew Gennery, Sergio D. Rosenzweig, Antonio Condino-Neto, Gholamreza Azizi, Hosein Rafiemanesh, Gholamreza Hassanpour, Nima Rezaei, Hassan Abolhassani, Asghar Aghamohammadi
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Lung disease is a frequent clinical manifestation in people living with primary immunodeficiency diseases, the most prevalent of which are common variable immunodeficiency disorders (CVID). CVID is primarily characterised by antibody deficiency, but recent definitions and diagnostic criteria recognise a much more complex pattern of immunological defects [1]. CVID can be classified into two major clinical phenotypes. One group experiences infection as the only major clinical manifestation, whilst the other present a variety of lymphoproliferative, inflammatory and/or autoimmune complications.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
cco G Abstract Ataxia Telangiectasia (AT) and Aicardi Goutières syndrome (AGS) are inherited disorders of immunity with prevalent neurological phenotype. Available treatments are only partially effective and the prognosis is poor. Induced pluripotent stem cells (iPSCs) are obtained by reprogramming patient somatic cells preserving the donor individual genetic heritage and creating patient specific disease models, useful to investigate pathogenesis, drug effects and to develop precision therapies. The aim is to investigate the cytotoxicity of a panel of immunomodulators using iPSCs of patients with AT or dif...
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Pharmacol Ther Source Type: research
Activated PI3K delta syndrome (APDS) belongs to the heterogeneous group of primary immunodeficiency disorders (PIDs). Progress in next-generation sequencing (NGS) enabled identification of gain-of-function mut...
Source: Allergy, Asthma and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Case report Source Type: research
Early detection of Primary Immunodeficiencies Disorders (PIDDs) is of paramount importance for effective treatment and disease management. Many PIDDs would be strong candidates for newborn screening (NBS) if robust screening methods could identify patients from dried blood spots (DBS) during the neonatal period. As majority of congenital PIDDs result in the reduction or absence of specific proteins, direct quantification of these target proteins represents an attractive potential screening tool. Unfortunately, detection is often limited by the extremely low protein concentrations in blood cells and limited blood volume pre...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study aimed to identify potential biomarkers of neonatal sepsis and explore its underlying mechanisms. METHODS: We downloaded the neonatal sepsis-related gene profile GSE25504 from the NCBI Gene Expression Omnibus (GEO) database. The differentially expressed RNAs (DERs) were screened and identified using LIMMA. Then, the functions of the DERs were evaluated using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. Finally, a competing endogenous RNA (ceRNA) network was constructed and functional analyses were performed. RESULTS: The initial screen identified 444 differ...
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research
AbstractThe transcription factor IRF8 (ICSBP) is required for the development and maturation of myeloid cells (dendritic cells, monocytes, macrophages), and for expression of intrinsic anti-microbial function such as antigen capture, processing and presentation to lymphoid cells, and for activation of these cells in response to cytokines and pro-inflammatory stimuli (IFN- γ, IFN-β, LPS).IRF8 deficiency in humans causes a severe primary immunodeficiency presenting as susceptibility to infections, complete or severe depletion of blood dendritic cells (DC) subsets, depletion of CD14+ and CD16+ monocytes and reduced...
Source: Human Genetics - Category: Genetics & Stem Cells Source Type: research
In conclusion, the present findings indicate that MYBL2 may be used as an independent prognostic factor in patients with ccRCC. PMID: 32218829 [PubMed - as supplied by publisher]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Papachristou SG, Iosifidis E, Sipsas NV, Gamaletsou MN, Walsh TJ, Roilides E Abstract Introduction: Osteoarticular fungal infections (OAFIs) complicate the clinical course of high-risk patients, including immunosuppressed individuals. Their management, however, despite being intricate, is governed by evidence arising from sub-optimal quality research, such as case series. Guidelines are scarce and when present result in recommendations based on low quality evidence. Furthermore, the differences between the management of immunocompromised and immunocompetent patients are not distinct. This is a narrative re...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
Allogeneic hematopoietic cell transplantation (HCT) offers curative therapy for patients with non-malignant diseases, including primary immunodeficiencies, bone marrow failure syndromes, hemophagocytic disorders, metabolic disorders and hemoglobinopathies. Historically, myeloablative regimens have been used; however, this has been associated with increased risk for morbidity and mortality due to comorbidities as a result of their underlying disease. Therefore, less intense regimens are required.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Gammagard Liquid | Primary Immunodeficiency Disease | Privigen